Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : WPI Watson Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: terri acey who wrote (23)	10/26/1998 8:38:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 61

Here's what Bear Stearns had to say about WPI acquiring THRT: ***Chairmen and CEO of Watson Allen Chao indicated that TheraTech's broad based drug delivery platform and that its portfolio of validated technologies makes it a meaningful addition to Watson. Additionally, TheraTech provides Watson with additional products for entry into Watson's core therapeutic categories and potentially new areas. TheraTech has new products in Women's Health and Dermatology. According to published reports, TheraTech's sales are expected to be approximately $40 million in 1999.